News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

The Hidden Agenda Behind the FDA's New Avandia Hearings


5/23/2013 8:34:50 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

On June 5 and 6, the FDA will convene an advisory committee meeting on the diabetes drug Avandia, which was removed from the market in 2010 in most countries and placed under severe restrictions in the United States. Currently, only 3000 patients take what was once the best-selling oral diabetes treatment in the world. Its maker, GlaxoSmithkline (GSK), did not seek this public meeting and has publicly stated that it did not request modification to the drug’s extremely restrictive label. In 2012, GSK pled guilty to criminal misconduct related in part to concealing the hazards of Avandia and paid a $3 billion fine, one of the largest in U.S. history. In this context, why is the FDA seeking a new review of Avandia?

Hey, check out all the research scientist jobs. Post your resume today!

Read at Forbes


comments powered by Disqus
Forbes
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES